Induction of Heme Oxygenase-1 Expression Is Dependent on Oxidative Stress and Reflects Treatment Outcomes
Overview
Authors
Affiliations
The antioxidant enzyme heme oxygenase-1 (HO-1) is implicated in the pathogenesis of tuberculosis (TB) and has been proposed as a biomarker of active disease. Nevertheless, the mechanisms by which () induces HO-1 as well as how its expression is affected by HIV-1 coinfection and successful antitubercular therapy (ATT) are poorly understood. We found that HO-1 expression is markedly increased in rabbits, mice, and non-human primates during experimental infection and gradually decreased during ATT. In addition, we examined circulating concentrations of HO-1 in a cohort of 130 HIV-1 coinfected and uninfected pulmonary TB patients undergoing ATT to investigate changes in expression of this biomarker in relation to HIV-1 status, radiological disease severity, and treatment outcome. We found that plasma levels of HO-1 were elevated in untreated HIV-1 coinfected TB patients and correlated positively with HIV-1 viral load and negatively with CD4 T cell count. In both HIV-1 coinfected and monoinfected patients, HO-1 levels were substantially reduced during successful TB treatment but not in those who experienced treatment failure or subsequently relapsed. To further delineate the molecular mechanisms involved in induction of HO-1 by , we performed a series of experiments using mouse and human macrophages. We found that -induced HO-1 expression requires NADPH oxidase-dependent reactive oxygen species production induced by the early-secreted antigen ESAT-6, which in turn triggers nuclear translocation of the transcription factor NRF-2. These observations provide further insight into the utility of HO-1 as a biomarker of both disease and successful therapy in TB monoinfected and HIV-TB coinfected patients and reveal a previously undocumented pathway linking expression of the enzyme with oxidative stress.
Zheng W, Borja M, Dorman L, Liu J, Zhou A, Seng A Sci Adv. 2025; 11(3):eadq8158.
PMID: 39813329 PMC: 11734715. DOI: 10.1126/sciadv.adq8158.
Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.
PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.
Yuan K, Yang Y, Lin Y, Zhou F, Huang K, Yang S Adv Sci (Weinh). 2024; 11(39):e2404453.
PMID: 39166412 PMC: 11497072. DOI: 10.1002/advs.202404453.
Redox Biomarkers in Asymptomatic Latent Human Tuberculosis: A Comparison With Active Disease.
Petrillo S, Di Prinzio R, Quatrana A, Santoro A, Torda C, Mastroianni C J Infect Dis. 2024; 230(5):e1162-e1170.
PMID: 38723117 PMC: 11565861. DOI: 10.1093/infdis/jiae254.
Castillo J, Neupane P, Karanika S, Krug S, Quijada D, Garcia A Antimicrob Agents Chemother. 2023; 68(2):e0104323.
PMID: 38132181 PMC: 10848751. DOI: 10.1128/aac.01043-23.